Newsfeeds - Spark Newswire

6 minute read

The Daily Biotech Pulse: Pfizer’s Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings

Today, 11:47 AM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3)

ABSI

5 minute read

The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen’s Anemia Drug, Corvus Shelves COVID Study

By Shanthi Rexaline

Today, 11:47 AM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 15)

ABCL

11 minute read

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

Today, 11:47 AM

During the morning session on Thursday, 152 stocks hit new 52-week lows.

ABCL

6 minute read

The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs

By Shanthi Rexaline

Today, 11:47 AM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14)

ABCL

5 minute read

The Daily Biotech Pulse: Lilly, Morphic’s Positive Data At ECCO, Humanigen’s COVID Treatment Gets Expedited Review In UK, TransCode IPO

By Shanthi Rexaline

Today, 11:47 AM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8)

ABCL

1 minute read

Akero’s NASH Candidate Shows Substantial Liver Fat Reductions After Four Months Of Treatment

By Vandana Singh

Today, 11:47 AM

Akero Therapeutics Inc (NASDAQ:AKRO) has announced full results of the main portion of its Phase 2a BALANCED trial of…

AKRO

3 minute read

FDA
News

Akero Therapeutics Highlights Study Published in Nature Medicine Shows Investigational NASH Drug Reduced Liver Fat to Normal Levels and Reversed Fibrosis After 16 Weeks of Treatment

By Benzinga Newsdesk

Today, 11:47 AM

Akero Therapeutics, Inc. (NASDAQ:AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced that full results of the main

AKRO

11 minute read

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

Today, 11:47 AM

Thursday morning, 158 companies reached new 52-week lows.

ABCL

2 minute read

News

Akero Therapeutics Presents at the American Diabetes Association’s 81st Scientific Sessions, Demonstrating that Improvements in Adipose Tissue Metabolism Contributed Substantially to Improved Liver Health and Better Glycemic Control in Efruxifermin (EF…

By Michael Horton

Today, 11:47 AM

AKRO

1 minute read

Akero Therapeutics New Analyses For Efruxifermin Shows Rapid, Substantial Liver Fat Reduction In NASH Patients

By Vandana Singh

Today, 11:47 AM

Akero Therapeutics Inc (NASDAQ:AKRO) has announced additional analyses from its Phase 2a BALANCED study of efruxifermin (EFX) in non-alcoholic steatohepatitis (NASH)…

AKRO